Aytu BioPharma, Inc. (AYTU)

Over the past six months, Aytu BioPharma reported Q1 fiscal 2026 net revenue of $13.9 million and a net income of $2.0 million. The company announced the commercial availability of EXXUA in the United States. AYTU shares gained 28% in December 2025. Aytu BioPharma held an Investor Day on January 20, 2026, focusing on EXXUA and its market opportunity. The company reported Q2 fiscal 2026 net revenue of $15.2 million and a net loss of $10.6 million. Aytu BioPharma entered into amended warrant agreements with institutional investors on March 31, 2026, to clarify beneficial ownership blockers. As of April 2, 2026, Aytu Biopharma's stock price was $2.68, with a market cap of $28.8M.

Demand seasonality for Aytu BioPharma's products and services is influenced more by market dynamics and product lifecycle than inherent seasonal patterns. The ADHD market experienced a normalization following competitor stimulant shortages. The pediatric portfolio experienced a decrease in net revenue in the past due to changes in payor coverage, but saw sequential revenue growth after the implementation of a return-to-growth plan. EXXUA is currently experiencing high demand, and its distribution is expanding through the Aytu RxConnect pharmacy network.

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic and Pharmaceuticals: Major industries. The company's business centers on commercializing prescription therapeutics, with a particular emphasis on complex central nervous system (CNS) diseases, including major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Major products include ADHD therapeutics (Adzenys XR-ODT, Cotempla XR-ODT, and Metadate CD), MDD therapeutic EXXUA, pediatric products (Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor), and a therapeutic development pipeline, including AR101/enzastaurin for vascular Ehlers-Danlos Syndrome (VEDS).

Aytu BioPharma, Inc. is headquartered in Denver, Colorado, United States. The company focuses on commercializing its therapeutics in the United States and internationally. It has expanded its product reach beyond the United States through international agreements, such as a commercial deal with Lupin Pharma Canada to commercialize its ADHD products in Canada, and has licensed rights to these ADHD products to Medomie Pharma for commercialization in Israel and the Palestinian Authority.

Aytu BioPharma positions itself as a company committed to improving the health and quality of life for patients by advancing innovative medicines for complex CNS diseases. The company emphasizes its patient-first approach and its Aytu RxConnect patient access program. Early feedback from patients on EXXUA has been positive, with reports of good tolerability and satisfaction.

Aytu BioPharma, Inc. has 40 institutional owners and shareholders holding a total of 3,771,501 shares. Major institutional owners include Nantahala Capital Management, LLC, Stonepine Capital Management, LLC, AWM Investment Company, Inc., Diadema Partners Lp, and Vanguard Group Inc. Institutional investors own approximately 33.49% of Aytu BioPharma's stock. The company was co-founded by Joshua R. Disbrow and Jarrett Disbrow in April 2015.